tbuckley/cabot-search huggingface dataset:
AB1019 Chronic Nonbacterial Osteomyelitis in a Pediatric Population: A Multicenter Observational Study
Authors: S. Pastore, G. Ferrara, C. Sandrin, L. Breda, M. Alessio, B. Teruzzi, S. Martino, V. Gerloni, M. Cattalini, A. Meini, F. La Torre, L. Lepore, A. Taddio
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Chronic nonbacterial osteomyelitis (CNO) is a rare inflammatory disorder that primarily affects children. Its hallmark is recurring episodes of sterile osteomyelitis. The clinical presentation is insidious onset of bone pain with or without fever. Pathogenesis is still unknown. <h3>Objectives</h3> We conducted a retrospective review to assess the clinical characteristics and treatment responses of a cohort of pediatric CNO patients. <h3>Methods</h3> Children diagnosed with CNO at 8 tertiary care centers in Italy between 2004 and 2014 were identified. Clinical, laboratory, radiological and histological data were obtained. <h3>Results</h3> Forty-seven patients with CNO (33 females, 14 males) were identified. The average follow up was 34 months (range 2 – 144 months). Bone pain was the leading symptom; median age of first complaint was 9 years (range 4-14 ys). A total of 210 localizations were found with a median of 4 localizations for patient. The majority of bone lesions were located in the metaphyses of the long bones (38%), vertebral column (35%), pelvis (12%) and clavicle (8%). Six patients had only one localization and 3 of them had the clavicle involvement. Sixteen out of 47 patients (34%) presented extra-articular symptoms: fever (13), psoriasis (5, one of them had acrodermatitis continua of Hallopeau), proteinuria (4), growth failure (2), acne (2), pustolosis (2), acrocyanosis (1). One out of 4 patients with proteinuria underwent renal biopsy that showed a mesangial glomerulonephritis. One other patient presented a steroid-dependent nephrotic syndrome before the onset of bone symptoms; renal biopsy showed a minimal change glomerulonephritis disease. At onset blood examination revealed pronounced increased eritrosedimentation rate (ESR) and C-reactive protein (CRP) in 18 cases (38%); slight increased ESR and CRP in 7 cases (15%). In 35/47 (74%) patients diagnosis was formalized after biopsy. In the remaining patients diagnosis seemed clear for multifocal pattern, the peculiar localizations and/or the typical MRI images. NSAIDs were the first line therapy in all patients, with achievement clinical remission in 12/47 (25%). Corticosteroids were used in 24/47 patients with good response only in 12% of them. Among the other patients we chose bisphosphonate with good percentage of clinical remission (18/26, 70%). <h3>Conclusions</h3> In a Italian cohort of 47 children with CNO, skin and renal involvement were detected. Bisphosphonates were more likely to lead to clinical remission than NSAIDs and corticosteroids. So we think that CNO patients need a strict renal function control and bisphosphonates should be the first choice second-line treatment. <h3>Disclosure of Interest</h3> None declared
The clinical significance of the follow up of tumor markers in breast carcinoma
Authors: J. Finek, L. Holubec, O. Topolcan, V. Treska, E. Helmichova
Journal: Journal of Clinical Oncology (2005)

865 Background: The authors deals with the detection of early disease progression in breast cancer patients during follow up using tumor markers. Methods: The basic group of 1184 patients with breast carcinoma in follow up after primary therapy were examined from 1998 to 2004. Sera were examined using commercial kits CA 15–3 (MEIA, Abbot), CEA (IRMA,Immunotech), TPA (IRMA, Byk Sangtec), TPS (IRMA, Beki). The results were compared with the retrospectively confirmed clinical status of the patients. Statistical evaluation was performed with the SAS 6.12 software product (StatSoft Inc.). The authors calculated optimal cut offs and sensitivities for particular tumor markers at 95% level of specificity. Results: Tumor markers have a following sensitivities for detection of bone metastases (CA 15–3 53%,CEA 47%,TPA 36% and TPS 23%), liver metastases (CA 15–3 68%,CEA 53%, TPA 46% and TPS 31%), lung metastases (CA 15–3 57%,CEA 32%,TPA 43%) and TPS 32%), metastases into central nervous system (CA 15–3 45%,CEA 67%,TPA 51% and TPS 25%). Tumor markers have a high negative predictive values for detection of bone metastases (CA 15–3 94%,CEA 92%,TPA 92%,TPS 91%), liver metastases (CA 15–3 99%,CEA 99%, TPA 98%,TPS 98%), lung metastases (CA 15–3 97%,CEA 96%,TPA 96%,TPS 95%), metastases into central nervous system (CA 15–3 99%,CEA 99%,TPA 98%,TPS 99%) and lymphnodes metastases (CA 15–3 97%,CEA 96%,TPA 97%,TPS 96%). Tumor markers have insufficient sensitivity for the metastatic process into lymph nodes. Conclusions: For tumor disease follow up only CA 15–3 has sufficient sensitivities (at 95% specificities) for early diagnosis of metastatic process. In order to monitore tumor markers during follow up it is necessary to define, characterize and standardize precisely remission and progression of serum tumor marker values. If standardization is not implemented, an incorrect interpretation and unreliable evaluation of tumor markers occurs. No significant financial relationships to disclose.
Author's reply
Authors: Ike Iheanacho
Journal: BMJ (2007)

Burnand gives a predictable, if disappointing, response from an industry that has done very well out of the unequivocally flawed Pharmaceutical Price Regulation Scheme. In seeking to challenge the basic principles of value based systems, the response attempts to downgrade some instances of where such pricing has provided tangible societal benefits, while completely sidestepping other examples (such as the systems in Canada and Sweden). The dig at the Pharmaceutical Benefits Scheme in Australia is superficial and potentially misleading, and those seeking a more balanced view of the regulation of drug prices in that country (including recent changes) would do well to look elsewhere.1 2 3 4

Reforming the pricing system in the UK will require constructive contributions from the pharmaceutical industry, for which Burnand's comments are a poor model.
DIAGNOSTIC CLINICS FOR PRIVATE AMBULATORY PATIENTS
Authors: R P McCOMBS
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Associations of Residential Long-Term Air Pollution Exposures and Satellite-Derived Greenness with Insulin Resistance in German Adolescents
Authors: Elisabeth Thiering, Iana Markevych, Irene Brüske, Elaine Fuertes, Jürgen Kratzsch, Dorothea Sugiri, Barbara Hoffmann, Andrea von Berg, Carl-Peter Bauer, Sibylle Koletzko, Dietrich Berdel, Joachim Heinrich
Journal: Environmental Health Perspectives (2016)

Epidemiological studies have identified associations between air pollution and green space access with type 2 diabetes in adults. However, it remains unclear to what extent associations with greenness are attributable to air pollution exposure.We aimed to investigate associations between long-term exposure to air pollution and satellite-derived greenness with insulin resistance in adolescents.A total of 837 participants of two German birth cohorts (LISAplus and GINIplus) were included in the analysis. Generalized additive models were used to determine the association of individual satellite-derived greenness defined by the Normalized Difference Vegetation Index (NDVI), long-term air pollution exposure estimated by land-use regression (LUR) models with insulin resistance (HOMA-IR) in 15-year-old adolescents. Models were adjusted for study area, cohort, socioeconomic, and individual characteristics such as body mass index, physical activity, and smoking.Increases of 2 SDs in nitrogen dioxide (NO2; 8.9 μg/m3) and particulate matter ≤ 10 μm in diameter (PM10; 6.7 μg/m3) were significantly associated with 11.4% (95% CI: 4.4, 18.9) and 11.4% (95% CI: 0.4, 23.7) higher HOMA-IR. A 2-SD increase in NDVI in a 1,000-m buffer (0.2 units) was significantly associated with a lower HOMA-IR (-7.4%; 95% CI: -13.3, -1.1). Associations tended to be stronger in adolescents who spent more time outside and in those with lower socioeconomic status. In combined models including both air pollution and greenness, only NO2 remained significantly associated with HOMA-IR, whereas effect estimates for all other exposures attenuated after adjustment for NO2.NO2, often considered as a marker of traffic, was independently associated with insulin resistance. The observed association between higher greenness exposure and lower HOMA-IR in adolescents might thus be attributable mainly to the lower co-exposure to traffic-related air pollution.Thiering E, Markevych I, Brüske I, Fuertes E, Kratzsch J, Sugiri D, Hoffmann B, von Berg A, Bauer CP, Koletzko S, Berdel D, Heinrich J. 2016. Associations of residential long-term air pollution exposures and satellite-derived greenness with insulin resistance in German adolescents. Environ Health Perspect 124:1291-1298; http://dx.doi.org/10.1289/ehp.1509967.
Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serum
Authors: H C Stancer, K L Reed
Journal: American Journal of Psychiatry (1986)

Desipramine and its metabolite 2-hydroxydesipramine were measured in the milk of a nursing mother and in the plasma of the mother and infant during administration of 300 mg/day of desipramine to the mother. Similar concentrations of both compounds were found in maternal plasma and milk. A pharmacokinetic plot of the milk over 24 hours showed the expected rise and fall of the substances following a single nighttime dose. Neither parent compound nor metabolite could be detected in the infant's serum even though the measurements were made shortly after peak ingestion by the infant. Furthermore, no clinical signs of toxicity were observed in the infant after 3 weeks of treating the mother with desipramine.
The National Library of Medicine
Authors: L Brooke
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Complex partial status epilepticus simulating psychogenic unresponsiveness
Authors: M E Drake, C E Coffey
Journal: American Journal of Psychiatry (1983)

P rolonged ictal disturbance of consciousness in generalized seizure disorders has been well described as absence status or spike wave stupor (1). A beclouded state from continuous or recurrent complex partial seizures is less frequently encountered. Complex partial status epilepticus may be difficult to recognize clinically, and the ictal character of the EEG may not be evident. The possibility of persistent postictal cognitive disturbance (2) underscores the importance of prompt diagnosis and therapy. We studied two patients with complex partial status epilepticus both clinically and electroencephalographically. Recognition of the ictal character of their behavior was impeded by the presence of clinical features associated with feigned or psychogenic unresponsiveness. In addition, in one patient complex partial status epilepticus was the initial manifestation of a seizure disorder and appeared at an age beyond the range previously associated with complex partial seizures.
PWE-055 Stigma in inflammatory bowel disease: building resilience
Authors: L Dibley, C Norton, E Mason-Whitehead
Journal: Gut (2015)

<h3>Introduction</h3> A stigma is a deeply discrediting attribute, often contravening social norms and viewed by others as undesirable.<sup>1</sup>People with IBD endure symptoms of diarrhoea and urgency, and 74% have some experience of faecal incontinence (FI).<sup>2</sup>IBD and related FI may lead to stigma through violation of social hygiene rules. <h3>Method</h3> This qualitative study aimed to: a) understand the experience of stigma in people with IBD and whether stigma derives from the bowel disorder diagnosis or from related FI; b) understand how stigma affects social, personal and emotional wellbeing, and how people with IBD manage these issues. Using purposive stratified sampling, 40 members of a UK IBD charity were recruited. Participants self-identified as having FI or not, and feeling stigmatised or not. Stigma was described as: <i>being, or feeling that you are being treated differently, feeling ashamed or guilty, worrying that others will find out about your illness, or that others will think badly of you because of your illness</i>. Unstructured individual interviews took place in participants’ homes. Data were analysed using an interpretive method. <h3>Results</h3> Three themes emerged: <i>Being in and out of control </i>(emotional command of one’s situation), <i>Relationships and Social Support </i>(intimate, family and professional helping networks), and <i>Mastery and Mediation </i>(adjusting to/balancing demands of IBD and life). Stigma arises from both IBD and FI due to socio-cultural demands of physical control over bodily functions, causing distress and social isolation. Attitudes towards bodily fluids and functions learnt in childhood, personality, humour, mental health, and perspective affect the stigma experience. Adults who create robust support networks, develop a sense of emotional control, and gain mastery of their situation are more likely to become stigma-resilient over time. <h3>Conclusion</h3> Clinicians can identify the stigma-vulnerable by asking patients about childhood attitudes towards bodily functions, and assessing personality and self-efficacy mechanisms. Patients can be more rapidly helped towards stigma-resilience and normalisation by learning to assess disease-related risks, e.g. incontinence, and make contingency plans (achieving emotional control), by learning how to tell others about IBD to secure their help (actively seeking supportive relationships), and by learning to do things differently in order to achieve tasks (mastery of IBD and life). Further research is needed to develop stigma-reduction strategies to improve quality of life for people with IBD. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Goffman E. <i>Stigma</i>: Notes on the management of a spoiled identity. Englewood Cliffs: Prentice-Hall Inc.; 19632 Norton C, Dibley L, Bassett, P. Faecal incontinence in inflammatory bowel disease (IBD): associations and effect on quality of life. <i>J Crohn’s Colitis</i>. 2013;7(8):e302–311
FRI0549 Magnetic Resonance Imaging Structural Alterations Associated with Active Discopathy of the Lumbar Spine: Identification of Two Phenotypically Distinct Subsets of Vertebral Endplate Modic 1 Signal Changes
Authors: C. Nguyen, M. Jousse, K. Sanchez, A. Feydy, M. Revel, M.-M. Lefèvre-Colau, S. Poiraudeau, F. Rannou
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Active discopathy detected on magnetic resonance imaging (MRI), and also known as Modic 1 signal changes, encompasses clinical, radiological and biological features, enabling to define a specific subset of patients with chronic low back pain (cLBP). Modic 1 changes are largely associated with degenerative disc disease (DDD) features, however we hypothesized that a specific subset of Modic 1 patients may display milder DDD. <h3>Objectives</h3> To determine Modic 1 MRI-associated structural alterations, and to identify Modic 1 subsets based on MRI findings. <h3>Methods</h3> MRI computerized database of a tertiary care hospital in France was searched between 01/01/2006 and 01/31/2008. MRI of the lumbar spine were systematically screened by two assessors. When Modic 1 changes were present at a single level on both adjacent endplates, MRI were considered eligible, and demographics and MRI-associated structural changes were assessed. <h3>Results</h3> Out of 12,840 recorded MRI, 101 MRI were eligible. Patients9 mean age was 56.6 (13.4) years and 41 (40.6%) were males. Modic 1 changes were more frequent at L4/L5 and L5/S1 levels (37[36.6%], respectively). The most frequent MRI-associated structural alterations were &gt;50% intervertebral space narrowing (IVSN) (70[69.3%]), anterior (51[50.5%]) and posterior (56[55.4%]) disc herniations, and anterior (68[67.3%]) and lateral (59[58.4%]) osteophytes. ≤50% IVSN Modic 1 differed from &gt;50% IVSN Modic 1. On bivariable analysis, patients were younger (51.5[14.1] <i>vs</i> 58.8[12.6] years, <i>p</i>=0.019), ≤50% IVSN Modic 1 were more often located at L5/S1 level (19[61.3%] <i>vs</i> 18[25.7%], <i>p</i>=0.001), and anterior and lateral osteophytes were less frequent (13[41.9%] <i>vs</i> 55[78.6%], <i>p</i>&lt;0.001, and 11[35.5%] <i>vs</i> 48[68.6%], <i>p</i>=0.002, respectively). On multivariable analysis, variables independently associated with &gt;50% IVSN Modic 1 were location at L4/L5 level, anterior disc herniation and lateral osteophyte. <h3>Conclusions</h3> Modic 1 changes are frequently associated with MRI DDD features. However, we identified a distinct ≤50% IVSN Modic 1 subset that occurs in younger patients, and is associated with less advanced DDD features. <h3>Disclosure of Interest</h3> None declared
Retinol-Binding Protein 4 and Insulin Resistance
Authors: Naoyuki Takashima, Hitonobu Tomoike, Naoharu Iwai
Journal: New England Journal of Medicine (2006)

To the Editor: Graham et al. (June 15 issue)1 report that serum levels of retinol-binding protein 4 (RBP4) correlated with the magnitude of insulin resistance in various subjects. However, RBP4 and plasma insulin levels were dissociated in subjects who did not have an improvement in insulin sensitivity after exercise.1 Thus, we believe that the importance of RBP4 should be assessed in more diverse groups. We assessed serum RBP4 levels in 473 subjects with normal glucose tolerance (fasting blood glucose level, <110 mg per deciliter) who were randomly selected from the Suita Study, an epidemiologic cohort study.2 Serum RBP4 levels correlated with triglyceride and uric acid levels and tended to correlate with glycated hemoglobin values and levels of high-density lipoprotein (HDL) cholesterol (Table 1). However, RBP4 levels did not correlate with the fasting blood glucose level, waist-to-hip ratio, body-mass index (BMI), systolic blood pressure, or fasting insulin level. Even in the 38 subjects with a family history of diabetes, RBP4 did not correlate with the fasting insulin level. Thus, it seems unlikely that RBP4 will be useful for assessing the risk of type 2 diabetes in Japanese people. The biologic action of RBP4 in relation to the action of insulin will need to be clarified to explain this inconsistency. Naoyuki Takashima, M.D. Hitonobu Tomoike, M.D., Ph.D. Naoharu Iwai, M.D., Ph.D.
Registry on Adverse Reactions
Authors: J D SCHNEIDAU, L M LAMAR, M A HAIRSTON
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
“Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold” [J. Control. Release 117 (2006) 380–386]
Authors: Hossein Hosseinkhani, Mohsen Hosseinkhani, Ali Khademhosseini, Hisatoshi Kobayashi
Journal: Journal of Controlled Release (2016)